Accreditation Statistics

As of June 3, 2024

Cellular Therapy Entities

  • Accredited: 262
  • Applicants: 30

Cord Blood Banks

  • Accredited: 48
  • Applicants: 10


Initial Accreditations

  • Cord Blood Bank University Hospital Basel Cord Blood Collection (Fixed and Non-Fixed sites), Banking, and Release for Administration of Unrelated and Related Donations
  • Cord Blood Bank Geneva Cord Blood Collection (Fixed, Non-Fixed sites), Banking, and Release for Administration of Unrelated and Related Donations


A complete list of accredited organizations can be found at

Just the FACTs 2024, Volume 3

Posted in :: 2024 Volume 3 :: Monday, June 24th, 2024

President’s Letter

We are excited to publish this June newsletter because the articles underscore the importance of the FACT accreditation process to enhance patient access to quality cellular therapy.

After years of meetings, presentations, and brainstorming, a solution to the unsustainable audit burden on health care sites and cell product manufacturers is here! FACT Audit & Assessment Services (FAAS), provided by FACT Consulting, is now available. In late 2023, a pilot project validated our processes, and we received positive feedback from three cell therapy companies and three apheresis facilities. If you are a site that is approached to undergo a company audit, suggest that the company contact us for our services. If you are a cell therapy company, we suggest initiating an assessment program with us so that we can customize our processes to your needs. I refer you to the informative article in this newsletter for more details.

In addition, I am delighted to highlight that we continue to accredit programs around the world, and in this newsletter we congratulate the Abu Dhabi Stem Cells Center on its initial accreditation for cellular therapy product processing with minimal manipulation – the first FACT accredited program in the United Arab Emirates!

Finally, to expand our services and global footprint, we are also keenly in tune to the need for more quality cellular therapy programs. To increase awareness, Blood Advances recently published an article submitted by our Immune Effector Cell (IEC) Task Force emphasizing the importance of quality systems and FACT accreditation for immune effector cellular therapy programs. Please feel free to share this open access article with your colleagues interested in providing these therapies and encourage them to seek FACT accreditation!


Catherine Bollard, MD

FACT President